BioMarin Pharmaceutical Stock Forecast, Price & News

-1.08 (-1.30 %)
(As of 06/18/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.34 million shs
Average Volume1.12 million shs
Market Capitalization$14.97 billion
P/E Ratio20.17
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive BMRN News and Ratings via Email

Sign-up to receive the latest news and ratings for BioMarin Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

BioMarin Pharmaceutical logo

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; and Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; vosoritide that is in Phase III clinical trial for the treatment of achondroplasia, a form of disproportionate short stature in humans; BMN 307, an AAV5 mediated gene therapy, which is in phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; BMN 331 for the treatment of hereditary angioedema; BMN 255 for the treatment of chronic renal disease; and BMN 351 for the treatment of Duchenne Muscular Dystrophy. The company has collaboration and license agreements with Sarepta Therapeutics, Asubio Pharma Co., Ltd., and DiNAQOR AG. The company serves specialty pharmacies, hospitals, and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has collaboration with Allen Institute. BioMarin Pharmaceutical Inc. was incorporated in 1996 and is headquartered in San Rafael, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

2.23 out of 5 stars

Medical Sector

27th out of 2,100 stocks

Pharmaceutical Preparations Industry

11th out of 831 stocks

Analyst Opinion: 3.3Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 3.1 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

BioMarin Pharmaceutical (NASDAQ:BMRN) Frequently Asked Questions

Is BioMarin Pharmaceutical a buy right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last twelve months. There are currently 7 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BioMarin Pharmaceutical stock.
View analyst ratings for BioMarin Pharmaceutical
or view top-rated stocks.

What stocks does MarketBeat like better than BioMarin Pharmaceutical?

Wall Street analysts have given BioMarin Pharmaceutical a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but BioMarin Pharmaceutical wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is BioMarin Pharmaceutical's next earnings date?

BioMarin Pharmaceutical is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for BioMarin Pharmaceutical

How were BioMarin Pharmaceutical's earnings last quarter?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced its quarterly earnings data on Wednesday, April, 28th. The biotechnology company reported $0.09 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.07 by $0.02. The biotechnology company had revenue of $486.03 million for the quarter, compared to analyst estimates of $445.44 million. BioMarin Pharmaceutical had a net margin of 43.11% and a trailing twelve-month return on equity of 2.77%.
View BioMarin Pharmaceutical's earnings history

How has BioMarin Pharmaceutical's stock price been impacted by Coronavirus?

BioMarin Pharmaceutical's stock was trading at $86.90 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BMRN stock has decreased by 5.8% and is now trading at $81.90.
View which stocks have been most impacted by COVID-19

What guidance has BioMarin Pharmaceutical issued on next quarter's earnings?

BioMarin Pharmaceutical issued an update on its FY 2021 earnings guidance on Thursday, May, 6th. The company provided earnings per share guidance of - for the period. The company issued revenue guidance of $1.75 billion-$1.85 billion, compared to the consensus revenue estimate of $1.81 billion.

What price target have analysts set for BMRN?

15 brokerages have issued 1-year target prices for BioMarin Pharmaceutical's shares. Their forecasts range from $82.00 to $218.00. On average, they anticipate BioMarin Pharmaceutical's share price to reach $116.17 in the next twelve months. This suggests a possible upside of 41.8% from the stock's current price.
View analysts' price targets for BioMarin Pharmaceutical
or view top-rated stocks among Wall Street analysts.

Who are BioMarin Pharmaceutical's key executives?

BioMarin Pharmaceutical's management team includes the following people:
  • Mr. Jean-Jacques Bienaime M.B.A., MBA, Chairman & CEO (Age 68, Pay $3.06M)
  • Mr. Brian R. Mueller, Exec. VP & CFO (Age 47, Pay $985.51k)
  • Dr. C. Greg Guyer Ph.D., CTO and Exec. VP of Global Manufacturing & Technical Operations (Age 59, Pay $1.07M)
  • Mr. Jeffrey Robert Ajer, Exec. VP & Chief Commercial Officer (Age 59, Pay $1.05M)
  • Dr. Henry J. Fuchs, Pres of Worldwide R&D (Age 63, Pay $1.34M)
  • Ms. Andrea L. Acosta, Group VP & Chief Accounting Officer (Age 42)
  • Mr. Lon Cardon Ph.D., Chief Scientific Strategy Officer (Age 55)
  • Traci McCarty, VP of Investor Relations
  • Mr. George Eric Davis, Exec. VP, Gen. Counsel & Sec. (Age 50)
  • Mr. Philip Lo Scalzo, Sr. VP & Chief Compliance Officer

What is Jean-Jacques Bienaimé's approval rating as BioMarin Pharmaceutical's CEO?

161 employees have rated BioMarin Pharmaceutical CEO Jean-Jacques Bienaimé on Jean-Jacques Bienaimé has an approval rating of 94% among BioMarin Pharmaceutical's employees. This puts Jean-Jacques Bienaimé in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of BioMarin Pharmaceutical's key competitors?

What other stocks do shareholders of BioMarin Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), (MDVN) (MDVN), Incyte (INCY), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), Vertex Pharmaceuticals (VRTX), (KITE) (KITE) and Freeport-McMoRan (FCX).

What is BioMarin Pharmaceutical's stock symbol?

BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN."

Who are BioMarin Pharmaceutical's major shareholders?

BioMarin Pharmaceutical's stock is owned by many different retail and institutional investors. Top institutional investors include Primecap Management Co. CA (9.94%), Ameriprise Financial Inc. (3.41%), Clearbridge Investments LLC (2.74%), Janus Henderson Group PLC (2.73%), Parnassus Investments CA (1.47%) and UBS Asset Management Americas Inc. (1.22%). Company insiders that own BioMarin Pharmaceutical stock include Brian Mueller, David E I Pyott, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Michael G Grey, Richard A Meier, V Bryan Lawlis and Willard H Dere.
View institutional ownership trends for BioMarin Pharmaceutical

Which major investors are selling BioMarin Pharmaceutical stock?

BMRN stock was sold by a variety of institutional investors in the last quarter, including Clearbridge Investments LLC, Janus Henderson Group PLC, TCW Group Inc., Fred Alger Management LLC, Alliancebernstein L.P., Millennium Management LLC, Polar Capital Holdings Plc, and UBS Asset Management Americas Inc.. Company insiders that have sold BioMarin Pharmaceutical company stock in the last year include Brian Mueller, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Michael G Grey, Richard A Meier, and Willard H Dere.
View insider buying and selling activity for BioMarin Pharmaceutical
or view top insider-selling stocks.

Which major investors are buying BioMarin Pharmaceutical stock?

BMRN stock was purchased by a variety of institutional investors in the last quarter, including Ameriprise Financial Inc., Parnassus Investments CA, Manning & Napier Group LLC, Renaissance Technologies LLC, Laurion Capital Management LP, Melqart Asset Management UK Ltd, Scout Investments Inc., and Canada Pension Plan Investment Board.
View insider buying and selling activity for BioMarin Pharmaceutical
or or view top insider-buying stocks.

How do I buy shares of BioMarin Pharmaceutical?

Shares of BMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioMarin Pharmaceutical's stock price today?

One share of BMRN stock can currently be purchased for approximately $81.90.

How much money does BioMarin Pharmaceutical make?

BioMarin Pharmaceutical has a market capitalization of $14.97 billion and generates $1.86 billion in revenue each year. The biotechnology company earns $859.10 million in net income (profit) each year or $0.68 on an earnings per share basis.

How many employees does BioMarin Pharmaceutical have?

BioMarin Pharmaceutical employs 3,059 workers across the globe.

When was BioMarin Pharmaceutical founded?

BioMarin Pharmaceutical was founded in 1997.

What is BioMarin Pharmaceutical's official website?

The official website for BioMarin Pharmaceutical is

Where are BioMarin Pharmaceutical's headquarters?

BioMarin Pharmaceutical is headquartered at 770 Lindaro Street, San Rafael CA, 94901.

How can I contact BioMarin Pharmaceutical?

BioMarin Pharmaceutical's mailing address is 770 Lindaro Street, San Rafael CA, 94901. The biotechnology company can be reached via phone at 415-506-6700 or via email at [email protected]

This page was last updated on 6/21/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.